MindMed engages renowned psychedelic-assisted therapy expert Dr Peter Gasser as an advisor to its LSD experiential therapy program Project Lucy

Mind Medicine (MindMed) Inc. (OTCQB:MMEDF), the leading psychedelic pharmaceutical company, has engaged renowned psychedelic-assisted therapy expert Dr Peter Gasser as an advisor to its LSD experiential therapy program Project Lucy. Gasser has pioneered the legal, medical use of psychedelics through clinical research and compassionate access in Switzerland. He has served as the President of the Swiss Medical Society for Psycholytic Therapy since 1997. READ: MindMed says dosing concluded in Phase 1 study of its 18-MC molecule which was well tolerated in humans Through compassionate access in Switzerland, Dr Gasser holds several individual treatment permissions to treat patients with MDMA and LSD. Gasser and University Hospital Basel's Dr Matthias Liechti are conducting a Phase 2 trial of LSD assisted therapy for anxiety disorders. MindMed previously acquired the exclusive license to this ongoing Phase 2 trial through its collaboration agreement with the University Hospital Basel. MindMed's Project Lucy intends to start a Phase 2b human efficacy trial that will focus on experiential doses of LSD to treat anxiety disorders administered by a therapist. In a statement, MindMed co-founder and co-CEO JR Rahn commented:  "Dr Gasser is one of the leading global experts on psychedelic assisted therapy and it's an honor for us to work together as we build Project Lucy into a world class commercial drug development program. "Dr Gasser's vast experience and history treating patients as a therapist through compassionate access in Switzerland also interests the company and will have tremendous benefits to our patients." Gasser helped pioneer compassionate access for end of life psychedelic assisted therapy in Switzerland. This week, the Canadian health minister approved compassionate access of psilocybin assisted therapy for terminally ill patients. Rahn added: "Health Canada's recognition that psychedelic substances have medicinal value and potential benefit for patients is extremely encouraging for all of us in the psychedelic inspired medical space. “It takes a village of dedicated government officials, scientists, therapists and entrepreneurs to make impactful change for patients, and we hope additional clinical trials will compel regulators to further allow psychedelic inspired medicines to help the millions of patients suffering from mental health and addiction." MindMed is a neuro-pharmaceutical company that discovers, develops and deploys psychedelic-inspired medicines to improve health, promote wellness and alleviate suffering. The company has initiated or is initiating studies to evaluate potential treatments to help patients with ADHD, anxiety, cluster headaches and substance abuse. Contact the author at jon.hopkins@proactiveinvestors.com